Improved insulin action can also aid in weight control
Weight loss is modest, typically 1 to 3 pounds, as the dose is at the starting level
20% higher D30 engagement from new features launched September 22, 2025 is based on a pre-post analysis from August 22 to October 24, 2025 of D30 engagement in key in-app behaviours (completing any Home Screen Task, tapping the Bank button to bank rewards for steps, viewing the Health Report, logging medication, or reading an article)
Together, well work to support your journey toward abundant healthphysically, mentally, and emotionally
Roche announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity